Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca announced positive data from a phase III study (FALCON) on its breast cancer drug,
Faslodex (fulvestrant/500mg). (finance.yahoo.com)
Elekta’s Leksell Ga a K ife Icon, a precise and sophisticated system for radiosurgery treatment,
has been cleared for clinical use by Japanese and U.S. authorities. (businesswire.com)
Fresenius Medical Care has established a subsidiary focusing on regenerative medicine. Unicyte AG
will pursue research into kidney and liver diseases, diabetes and cancer. (nephrologynews.com)
Novartis opened its third global facility with a $1 billion research and development campus and a
capacity of 1’300 employees in Shanghai. (ibtimes.com)
Qiagen launched its liquid biopsy workflow for clinical cancer research using its GeneReader NGS
System for next-generation sequencing. Illumina filed for patent infringement. (prnewswire.com)
Roche’s subcutaneous formulation of MabThera (rituximab) has been approved by the EC for the
treatment of patients suffering from relapsed/refractory CLL. (finance.yahoo.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 14
2016-06-04
AstraZeneca Biogen Chugai Daiichi Sankyo Elekta Fresenius Medical Care
Gilead Sciences Kaken Medtronic Novartis Qiagen Roche Valeant Vertex
SPOTLIGHT
COMPANY NEWS
Biogen and AbbVie have won approval from the FDA for their new multiple sclerosis drug, Zinbryta
(daclizumab), that can be used at home and only requires one injection a month. (fiercebiotech.com)
Gilead Sciences gained a positive opinion for Epclusa, indicated for patients suffering from HCV
infection, from a committee of the European Medicines Agency. (businessfinancenews.com)
Medtronic reported fiscal Q4 earnings of $1.1 billion, compared with a loss of 1 million in the same
period a year ago. Revenue increased to $7.57 billion from $7.30 billion. (marketwatch.com)
Valeant rejected a combined takeover approach from Takeda and private-equity firm TPG. It came
before Valeant hired Joseph Papa as its new CEO. (finance.yahoo.com)
Vertex announced that the FDA has accepted for review a supplemental New Drug Application for
the use of ORKAMBI® (lumacaftor/ivacaftor). (smarteranalyst.com)
Chugai concluded a license agreement with Roche for SA237, an investigational, humanized
monoclonal antibody that targets the IL-6 receptor, created by Chugai. (pharmabiz.com)
Daiichi Sankyo said it will not proceed with the second part of its late-stage study on the lung cancer
drug, patritumab, as it did not meet the required efficacy criteria in the first part. (reuters.com)
Kaken and the Korea-based firm, Dong-A ST, concluded an exclusive distribution agreement for the
topical formulation for Onychomycosis "Clenafin / Jublia" in Korea. (reuters.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
Regional Comparison
Focus on Europe
98%
99%
100%
101%
102%
2016-05-30 2016-05-31 2016-06-01 2016-06-02 2016-06-03
Europe North America Asia/Pacific
This week’s sto k perfor a e of the world’s iggest listed health are o pa ies shows a negative
development of -0.4% while their one year loss reaches -6.0%. Strongest change occurred in the
European region with -1.2% on a weekly basis and -8.9% on a yearly basis. North America decreased
by -0.3% whereas Asia/ Pacific grew by +0.5%, showing -7.3% and +18.6% for one year respectively.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 14
2016-06-04
Coloplast Elekta Fresenius Medical Care Genmab Hikma
Indivior Stada Swedish Orphan UCB William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
Taki g a look at Europe’s top perfor er this week, the most striking candidate is Indivior, gaining
+36.6% on a weekly basis while its one year loss reaches -7.9%. Second winner from Europe is
William Demant with a gain of +6.6% this week, while its one year increase amounts to +21.6%.
Regarding the lower end of the weekly performance ranking, Elekta takes the lead due to its decline
of -5.9% compared to its one year growth of +11.4%. Next is Stada, suffering from a decrease of -
4.3% this week and scoring a one year performance of +51.4%.
top 5 companies closing price 1 week change 1 year change 1 week'shigh 1 week'slow 1 year'shigh 1 year'slow
Indivior 2.95 +36.68% -7.92% 3.06 2.16 3.89 1.61
William Demant 18.40 +6.63% +21.65% 19.05 18.40 19.05 3.57
Genmab 167.14 +5.39% +108.48% 167.30 156.77 167.44 67.98
Hikma 29.06 +4.76% +4.06% 29.75 28.28 35.02 21.35
UCB 66.89 +3.53% +0.20% 67.15 64.22 85.56 61.98
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Elekta 6.64 -5.98% +11.46% 7.07 6.61 8.11 5.50
Stada 47.37 -4.34% +51.45% 49.46 46.38 49.46 28.07
Swedish Orphan 11.66 -4.26% -18.04% 12.30 11.65 15.28 9.77
Coloplast 65.48 -3.72% -3.81% 68.24 64.98 78.58 55.69
Fresenius Medical Care 76.25 -2.87% -1.87% 78.85 75.98 83.50 63.11
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
741.32 -1.21% -8.97% 752.05 736.02 876.66 654.95
STOXX® North America 600
Health Care
834.84 -0.33% -7.36% 851.29 828.41 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
452.48 +0.52% +18.62% 454.18 444.26 454.80 349.32
STOXX® Global 1800
Health Care
737.10 -0.49% -6.09% 749.92 731.94 842.76 647.94